News|Articles|December 25, 2023

Top 3 Most Read DE&I Articles of 2023

Authors in this area focused on increasing diversity in clinical trials through patient-first payment options and trial design.

Below are the most read diversity, equity, and inclusion (DE&I) articles featured on Applied Clinical Trials in 2023.

1. Increasing Clinical Trial Diversity Through Patient-First Payment Options

Patient-first trial design, based around the tenets of adaptability and personalization, has emerged as a key solution to increase diversity and improve trial outcomes for all. There is an increasing focus on the need to flex trial designs to meet the needs of participants, whether they are logistical, financial, or educational.

However, uptake of new technologies that offer patient optionality is far from universal, in part due to the industry’s desire to stay in its comfort zone. This hesitation is particularly apparent in clinical trial payments.

Read the full article here.

2. 12 Questions We Need to Answer to Achieve Diversity in Clinical Research

DE&I has, deservedly, become a hot topic in clinical research. Numerous organizations are developing methodologies, products and programs. If “let a thousand flowers bloom” is the best way to achieve diversity, we are certainly on track. However, we should be able to minimize duplicative efforts and accelerate learning through collaboration. The best place to start this collaboration is to develop consensus answers to the following 12 fundamental questions.

Read the full article here.

3. The Impact of Trial Design on Interest by Race and Ethnicity

The life sciences industry is collectively recommitted to better addressing challenges to diversity and inclusion in clinical trials, especially among traditionally underserved populations. What we know is that there is no singular formula to effectively resolve this longstanding issue. As such, clinical trial sponsors, their contract research organization (CRO) partners, and other industry stakeholders are recognizing the importance of approaching each trial program with a deliberate focus on diversity goals during trial design and planning activities.

Read the full article here.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.